The Food and Drug Administration announced the renewed charter of the Blood Products Advisory Committee, effective Aug. 3.
The BPAC is a discretionary federal advisory committee established to provide advice to the commissioner of food and drugs. The BPAC reviews and evaluates available data concerning the safety, effectiveness and appropriate use of blood, products derived from blood and serum or biotechnology that are intended for use in the diagnosis, prevention or treatment of human diseases. The renewal authorizes the BPAC to operate until May 13, 2024.
